Literature DB >> 25255239

Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia.

Philippe Hantson1, Catherine Lambert, Cédric Hermans.   

Abstract

Heparin-induced thrombocytopenia (HIT) may be a critical condition in intensive care patients. Diagnosis of HIT is often difficult, and management too, as physicians have usually a limited experience with alternative anticoagulants. A 36-year-old man was admitted for orthopaedic surgery after a trauma causing a fracture of the sacrum and right ankle. Anticoagulant prophylaxis was made by nadroparin (3800  IU/day). But the patient developed less than 10 days after nadroparin exposure a significant drop in platelet count. The diagnosis of HIT was based on the pretest clinical score and demonstration of platelet factor 4 and heparin antibodies. Fondaparinux was transiently administered but was replaced 3 days later by rivaroxaban (15  mg twice a day during 21 days then 20  mg/day), after the demonstration of an acute thrombosis of the left radial artery. Platelet count returned to normal range and a partial recanalization of arterial thrombosis was noted. The use of rivaroxaban in this indication is of theoretical interest but requires further experience.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25255239     DOI: 10.1097/MBC.0000000000000205

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  8 in total

1.  Direct oral anticoagulants in hypercoagulable states.

Authors:  Paul R Kunk; Jacqueline Brown; Melissa McShane; Surabhi Palkimas; B Gail Macik
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 2.  Novel oral anticoagulants for heparin-induced thrombocytopenia.

Authors:  Jessica W Skelley; Jeffrey A Kyle; Rachel A Roberts
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

3.  Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia.

Authors:  Asmaa Albuloushi; Megan Rhoten; Julie Kelly; Katelyn W Sylvester; Jessica Grandoni; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2022-09-21       Impact factor: 5.221

4.  Rivaroxaban in treatment refractory heparin-induced thrombocytopenia.

Authors:  Joshua Misha Lewis Casan; George Grigoriadis; Noel Chan; Sanjeev Chunilal
Journal:  BMJ Case Rep       Date:  2016-08-12

5.  Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay.

Authors:  Preethi Ramachandran; Fady Farag; Rewais Morcus; Vladimir Gotlieb
Journal:  Am J Case Rep       Date:  2019-03-09

Review 6.  Dabigatran approaching the realm of heparin-induced thrombocytopenia.

Authors:  Patricia J Ho; Juan A Siordia
Journal:  Blood Res       Date:  2016-06-23

7.  Successful Treatment of Dual-Positive Anti-Myeloperoxidase and Anti-Glomerular Basement Membrane Antibody Vasculitis with Pulmonary-Renal Syndrome.

Authors:  Jinxian Huang; Ling Wu; Xiaoyan Huang; Yan Xie; Jinquan Yu; Jin Yang; Huiqiong Fang; Lijun Zhang
Journal:  Case Rep Nephrol Dial       Date:  2016-01-08

8.  Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience.

Authors:  Mohamed Aon; Omar Al-Shammari
Journal:  Case Rep Hematol       Date:  2020-09-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.